Medical Condition News

RSS

Gene study may uncover regulatory network that influences development of cardiovascular disease

University of North Carolina researchers have discovered that disrupting a gene that acts as a regulatory switch to turn on other genes can keep blood vessels from forming and developing properly.

30 Apr 2013

Naturopathic lifestyle counselling helps reduce risk of cardiovascular disease

Counselling and treatment with naturopathic care as well as enhanced usual care reduced the prevalence of metabolic syndrome, a risk factor for heart disease, by 17% over a year for participants in a randomized controlled trial published in CMAJ.

30 Apr 2013

New research shows more than a third of stroke patients don't get to hospital by ambulance

More than a third of stroke patients don't get to the hospital by ambulance, even though that's the fastest way to get there, according to new research in Circulation: Cardiovascular Quality and Outcomes, an American Heart Association journal.

30 Apr 2013

Merck, Pfizer sign collaboration agreement for development and commercialization of ertugliflozin

Merck & Co., Inc., known as MSD outside the United States and Canada, and Pfizer Inc. today announced that they have entered into a worldwide (except Japan) collaboration agreement for the development and commercialization of Pfizer's ertugliflozin (PF-04971729), an investigational oral sodium glucose cotransporter (SGLT2) inhibitor being evaluated for the treatment of type 2 diabetes.

From Pfizer, Inc. 30 Apr 2013

Maruishi gains exclusive rights to develop, commercialize Cara Therapeutics' CR845 in Japan

Cara Therapeutics, Inc. and Maruishi Pharmaceutical Company, Ltd. today announced that they have entered into a License Agreement providing Maruishi with exclusive rights to develop, manufacture and commercialize Cara's lead analgesic drug candidate, CR845, for acute pain and uremic pruritus in Japan.

29 Apr 2013

Alimera announces availability of ILUVIEN in U.K. for chronic DME treatment

Alimera Sciences, Inc., a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that ILUVIEN®, the first sustained release pharmaceutical product for the treatment of chronic diabetic macular edema, is now available in the United Kingdom.

29 Apr 2013

CVRx enrolls first patient in Barostim HOPE4HF clinical trial

CVRx, Inc., a private medical device company, announced the first patient enrolled in the Barostim HOPE4HF clinical trial. The study is evaluating the effectiveness and safety of CVRx's Barostim neo in heart failure patients.

29 Apr 2013

Oramed to report results of T1DM oral insulin formulation at Diabetes Summit 2013

Oramed Pharmaceuticals Inc., a developer of oral delivery systems of drugs currently administered by injection, announced today that its abstract, entitled "Oral insulin capsules toward management of Type 1 diabetes mellitus," will be presented at the Global Technology Community Diabetes Summit 2013.

29 Apr 2013

Veloxis seeks EMA approval to market LCP-Tacro for kidney transplant patients

Veloxis Pharmaceuticals A/S today announced that it has submitted a Marketing Authorization Application to the European Medicines Agency seeking approval to market LCP-Tacro for the prevention of organ rejection in kidney transplant patients in the European Union.

29 Apr 2013

Oxford BioTherapeutics, Boehringer Ingelheim team up to discover novel cancer antibody targets

Oxford BioTherapeutics and Boehringer Ingelheim today announce a new alliance focused on the discovery of novel cancer antibody targets that OBT will identify with the help of its OGAP® discovery platform.

29 Apr 2013

Heart Failure Congress 2013 to feature more than 100 scientific sessions on heart failure

The Heart Failure Congress 2013 promises more science than ever this year, with a record number of abstracts submitted. The congress takes place 25-28 May at the Centro de Congressos de Lisboa in Lisbon, Portugal.

29 Apr 2013

Study may pave way for new strategies to fight cancer cells

For the first time, researchers at Karolinska Institutet in Sweden have managed to obtain detailed images of the way in which the transport protein GLUT transports sugars into cells.

29 Apr 2013

Research provides new insights into the origin of brown fat cells

Scientists from ETH Zurich have shown for the first time that brown and white fat cells in a living organism can be converted from one cell type to the other.

29 Apr 2013

GWCI research focuses on real needs of adolescent, young adult cancer survivors

New research out of the George Washington University Cancer Institute focuses on the difficulties of transitioning to adulthood while dealing with the long-term and late effects of cancer and its treatment.

29 Apr 2013

UAB expert offers simple strategies to tackle summer allergy season

Sneezing, wheezing and coughing are just some of the symptoms that seasonal allergies can stir up. One sinus expert at the University of Alabama at Birmingham said despite a late spring, the summer allergy season will be strong.

29 Apr 2013

Intermittent fasting: A path to weight loss and improved cardiovascular risk

Intermittent fasting is all the rage, but scientific evidence showing how such regimes affect human health is not always clear cut. Now a scientific review in the British Journal of Diabetes and Vascular Disease published by SAGE, suggests that fasting diets may help those with diabetes and cardiovascular disease, alongside established weight loss claims.

29 Apr 2013

New treatment strategy for patients with CMT disease on the horizon

A potential new treatment strategy for patients with Charcot-Marie-Tooth disease is on the horizon, thanks to research by neuroscientists now at the University at Buffalo's Hunter James Kelly Research Institute and their colleagues in Italy and England.

29 Apr 2013

CHMP recommends approval of NUEDEXTA for treatment of pseudobulbar affect

Avanir Pharmaceuticals, Inc. today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion for NUEDEXTA (dextromethorphan hydrobromide and quinidine sulfate), recommending NUEDEXTA be approved for the treatment of pseudobulbar affect, irrespective of neurologic cause.

29 Apr 2013

MorphoSys initiates Phase 2 clinical trial of MOR208 in B-cell acute lymphoblastic leukemia patients

Xencor announced today that MorphoSys AG has dosed the first patient in a Phase 2 clinical trial of MOR208 in B-cell acute lymphoblastic leukemia.

29 Apr 2013

Doctors assail drugmakers for $100K cancer medicines

More than 100 cancer specialists call for pharmaceutical companies to lower the prices of these drugs that patients need to live.

29 Apr 2013

Medical Condition News

Gene study may uncover regulatory network that influences development of cardiovascular disease

Naturopathic lifestyle counselling helps reduce risk of cardiovascular disease

New research shows more than a third of stroke patients don't get to hospital by ambulance

Merck, Pfizer sign collaboration agreement for development and commercialization of ertugliflozin

Maruishi gains exclusive rights to develop, commercialize Cara Therapeutics' CR845 in Japan

Alimera announces availability of ILUVIEN in U.K. for chronic DME treatment

CVRx enrolls first patient in Barostim HOPE4HF clinical trial

Oramed to report results of T1DM oral insulin formulation at Diabetes Summit 2013

Veloxis seeks EMA approval to market LCP-Tacro for kidney transplant patients

Oxford BioTherapeutics, Boehringer Ingelheim team up to discover novel cancer antibody targets

Heart Failure Congress 2013 to feature more than 100 scientific sessions on heart failure

Study may pave way for new strategies to fight cancer cells

Research provides new insights into the origin of brown fat cells

GWCI research focuses on real needs of adolescent, young adult cancer survivors

UAB expert offers simple strategies to tackle summer allergy season

Intermittent fasting: A path to weight loss and improved cardiovascular risk

New treatment strategy for patients with CMT disease on the horizon

CHMP recommends approval of NUEDEXTA for treatment of pseudobulbar affect

MorphoSys initiates Phase 2 clinical trial of MOR208 in B-cell acute lymphoblastic leukemia patients

Doctors assail drugmakers for $100K cancer medicines

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News